Updated time: 2023-10-16 15:34:32
28A-1030530
US 10047166 B2、KR 10-1892837、JP 6397938、NZ 723520、AU 2015277379、CA 2943588、MX 371053、EP3157951、CN 106573972 B、IN 438919
A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.
The antibody can bind to CD23-bound IgE and effectively crosslink CD23 on B lymphocytes to result in inhibition of antigen-specific IgE production by B cells upon activation by a specific antigen.
Treatment of allergic diseases
CHEN JIUN-BO, SHIUNG YU-YU, CHANG TSE-WEN
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS